Dr Sáez-Cirión received his PhD in Science in 2001 from the University of the Basque Country, Leioa, Spain. He joined the Institut Pasteur in Paris as a Postdoc in 2003 after a first postdoctoral period at the FDA-CBER in Bethesda. He leads now a research team in the HIV Inflammation and Persistence Unit. His research is currently focused in understanding (i) the mechanisms underlying control of HIV infection in natural HIV controllers and post-treatment controllers in remission of HIV infection after interruption of antiretroviral treatment; (ii) the factors associated with the establishment of HIV reservoirs and devising new approaches to tackle them.
Humoral immunoprofiling in HIV-1 post-treatment controllers
Rare infected individuals who initiated antiretroviral therapy (ART) very early during primary infection can enter in remission after its interruption, a phenomenon known as post-treatment control. Interestingly, early treatment has been associated with the […]
The ANRS 12225-Pediacam study is coordinated by Mr. Tejiokem at the Center Pasteur in Cameroon. Since 2007, the project has included children exposed or infected with HIV-1 and a group of unexposed and uninfected […]
Archive of the Group for AIDS Research
This page contains the list of past meetings held by the Group for AIDS Research (Groupe de Réflexion SIDA) of the Pasteur Institute since 2014. The list of previous meetings held since 2002 can […]
Group for AIDS Research
The Group for AIDS Research (Groupe de Réflexion SIDA, GRS) organizes bimonthly meetings and seminars around an HIV / AIDS research topic. Since 2021, the meetings may also include topics related to emerging viruses. […]
ICISTEM-International Collaboration to guide and investigate the potential for HIV cure by Stem Cell Transplantation
ICISTEM is a collaborative project to guide and investigate the potential for HIV cure in HIV-infected patients requiring allogeneic stem cell transplantation for hematological disorders. The ICIISTEM consortium is composed of an expert European […]
Etude ANRS-EP59-CLEAC (Comparison of Late versus Early Antiretroviral therapy in HIV-infected Children) : Etude physiopathologique comparant l’impact de l’instauration précoce (avant 6 mois) ou tardive (après 2 ans) du traitement antirétroviral sur l’évolution immuno-virologique des enfants infectés par le VIH-1 en période périnatale)
A collaborative study with members of Pasteur Institute (A. Saez-Cirion, D. Scott-Algara), french perinatal cohort (ANRS CO10; J. Warszawsky) and 10 hospitals from Paris Area (Principal investigator, P. Frange). The study has included 76 […]
Natural Control of HIV-1 Infection
HIV-controllers (HIC) (also called “elite controllers” or “elite suppressors”) are rare (less than 1%) HIV-infected patients who control viral replication to undetectable levels in the absence of antiretroviral treatment. In the context of the […]
Role of CD8 T cells responses in the control of HIV-2 infection-ANRS Immunovir2
The number of persons living with HIV-1 is around 35 million while roughly one million persons are living with HIV-2, with a decreasing prevalence. Both HIV-1 and HIV-2 are associated with AIDS, however most HIV-2 […]
|2018-present||Associate Professor and Team Leader in the Unité HIV inflammation et persistance, Institut Pasteur, Paris, France.|
|2014-2017||Assistant Professor and Team Leader in the Unité HIV inflammation et persistance, Institut Pasteur, Paris, France.|
|2010-2014||Assistant Professor in the Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France.|
|2007-2009||Senior Scientist in the Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France.|
|2003-2007||Postdoctoral position in the Unité de Régulation des Infections Rétrovirales, Institut Pasteur, Paris, France. Research advisor: Dr. Gianfranco Pancino. Project: Mechanism of resistance to HIV-1 infection in human primary cells.|
|2002-2003||Postdoctoral position in the Division of Viral Products, Center for Biologics Evaluation and Research (CBER), U.S. Food and Drug Administration (FDA), Bethesda MD, USA. Research advisor: Dr. Carol D. Weiss. Project: Rational approaches to block HIV entry.|
|1998-2001||PhD student in the Unidad de Biofisica (CSIC-UPV/EHU), Department of Biochemistry, University of the Basque Country, Leioa, Spain. Research advisor: Prof. J.L. Nieva. Project: Mechanisms of virus-induced membrane fusion.|
|1995-1998||Undergraduate Student in the Unidad de Biofísica (CSIC-UPV/EHU), University of the Basque Country, Leioa, Spain. Research advisors: Prof. A. Alonso and Prof. E. A. Rivas. Projects: Effects of lipids in membrane fusion and Effects of surfactants in the different phases of lipids on model membranes.|
|2013||HDR in Life Sciences, Université Pierre et Marie Curie, Paris VI, Paris, France.|
|2001||PhD in Biochemistry and Molecular Biology, University of the Basque Country, Leioa, Spain. “Membrane interacting domains in virus and prions”. Suma Cum Laude.|
|2000||MSc degree, in Biochemistry. University of the Basque Country, Leioa, Spain.|
|1998||Graduated in Biochemistry, University of the Basque Country, Leioa, Spain.|
SOME ADDITIONAL PROFESSIONAL RESPONSABILITIES
|2017-present||President of Scientific and Medical Committee of SIDACTION|
|2014-present||Coordinator of the ANRS RHIVIERA consortium on HIV remission|
|2013-present||Coordinator of the ANRS International Post-Treatment Controllers cohort|
|2013-present||Member of the Scientific and Medical Committee of SIDACTION|
|2012-present||Member of the Scientific Committee of CO6 ANRS PRIMO cohort|
|2012-present||Member of Institut Pasteur’s Groupe de Réflexion sur le SIDA (GRS)|
|2012-present||Member of the Steering Committee of CO21 ANRS CODEX cohort|
|2011-2017||Co-president of the ANRS coordinated action AC32 “HIV reservoirs”|
|2010-2017||Elected Member of Institut Pasteur’s Virology Department Council|
2021Antiretroviral therapy for HIV controllers: Reasons for initiation and outcomes in the French ANRS-CO21 CODEX cohort., EClinicalMedicine 2021 Jul; 37(): 100963.
2021Ultrasensitive detection of p24 in plasma samples from people with primary and chronic HIV-1 infection., J Virol 2021 May; (): .
2021SIV-induced terminally differentiated adaptive NK cells in lymph nodes associated with enhanced MHC-E restricted activity., Nat Commun 2021 02; 12(1): 1282.
2021CD32+CD4+ T Cells Sharing B Cell Properties Increase With Simian Immunodeficiency Virus Replication in Lymphoid Tissues., Front Immunol 2021 ; 12(): 695148.
2021Immunometabolism and HIV-1 pathogenesis: food for thought., Nat. Rev. Immunol. 2021 Jan;21(1):5-19.
2020Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study., Cell Rep 2020 09; 32(12): 108174.
2020Affinity for the Interface Underpins Potency of Antibodies Operating In Membrane Environments., Cell Rep 2020 Aug; 32(7): 108037.
2020The genome-wide methylation profile of CD4+ T cells from HIV-infected individuals identifies distinct patterns associated with disease progression., Clin Infect Dis 2020 Jul; (): .
2020Antiapoptotic Clone 11-Derived Peptides Induce In Vitro Death of CD4+ T Cells Susceptible to HIV-1 Infection., J Virol 2020 07; 94(14): .
2020Extremely low viral reservoir in treated chronically HIV-1-infected individuals., EBioMedicine 2020 Jul; 57(): 102830.
+View full list of publications